The α2-adrenergic receptor agonist, clonidine, reduces alcohol drinking in alcohol-preferring (P) rats.
- Authors
- Rasmussen, Dennis D; Alexander, Laura; Malone, Julia; Federoff, David; Froehlich, Janice C
- Year
- 2014
- Journal
- Alcohol (Fayetteville, N.Y.)
- PMID
- 25085719
- DOI
- 10.1016/j.alcohol.2014.07.002
- PMCID
- PMC4163132
Evidence suggests that noradrenergic signaling may play a role in mediating alcohol-drinking behavior in both rodents and humans. We have investigated this possibility by administering clonidine to alcohol-drinking rats selectively bred for alcohol preference (P line). Clonidine is an α2-adrenergic receptor agonist which, at low doses, inhibits noradrenergic signaling by decreasing norepinephrine release from presynaptic noradrenergic neurons. Adult male P rats were given 24 h access to food and water and scheduled access to a 15% (v/v) alcohol solution for 2 h daily. Rats received intra-peritoneal (IP) injections with clonidine (0, 10, 20, 40, or 80 μg/kg body weight [BW], 10-11 rats/treatment group) once/day at 30 min prior to onset of the daily 2 h alcohol access period for 2 consecutive days. Clonidine, in doses of 40 or 80 μg/kg BW, significantly reduced alcohol intake on both days of treatment (p<0.001). Two weeks later, rats were treated with clonidine for 5 consecutive days and clonidine, in doses of 40 or 80 μg/kg BW, reduced alcohol intake on all 5 treatment days (p < 0.001). Clonidine did not alter water consumption during the daily 2 h free-choice between alcohol and water. In a separate group of male P rats, clonidine (40 μg/kg BW) suppressed intake of a saccharin solution (0.04 g/L). These results are consistent with and complement our previous findings that the α1-adrenergic receptor antagonist, prazosin, decreases voluntary alcohol drinking in alcohol-preferring rats, but suggests that effects of clonidine may not be specific for alcohol. The results suggest that although activation of the noradrenergic system plays an important role in mediating voluntary alcohol drinking, care is needed in selecting which drugs to use to suppress central noradrenergic signaling in order to maximize the selectivity of the drugs for treating alcohol-use disorders.
INITIAL 2-DAY TREATMENTEffects of clonidine (10, 20, 40, 80 µg/kg BW, IP) on 2-h alcohol intake by adult male P rats. Clonidine was injected on each of 2 consecutive days (Days 1 and 2) at 30 min prior to onset of a 2-h free-choice between alcohol (15% v/v) and water. ***p < 0.001 vs. saline control treatment, independent of drug treatment day; *p < 0.05 vs. previous saline control treatment, independent of post-drug day.
INITIAL 2-DAY TREATMENTEffects of clonidine (10, 20, 40, 80 µg/kg BW, IP) on 2-h water intake by adult male P rats. Clonidine was injected on each of 2 consecutive days (Days 1 and 2) at 30 min prior to onset of a 2-h free-choice between alcohol (15% v/v) and water.
SUBSEQUENT 5-DAY TREATMENTEffects of clonidine (10, 20, 40, 80 µg/kg BW, IP) on 2-h alcohol intake by adult male P rats. Clonidine was injected on each of 5 consecutive days (Days 1–5) at 30 min prior to onset of a 2-h free-choice between alcohol (15% v/v) and water. Alcohol was not available on weekends. The Pre-Drug Day was a Friday preceding Drug Days 1–5 (Monday–Friday of the following week) and Post-Drug Days 3 and 4 were on Monday and Tuesday of the week following termination of clonidine treatment. ***p < 0.001 vs. saline control treatment, independent of drug treatment day.
SUBSEQUENT 5-DAY TREATMENTEffects of clonidine (10, 20, 40, 80 µg/kg BW, IP) on 2-h water intake by adult male P rats. Clonidine was injected on each of 5 consecutive days (Days 1–5) at 30 min prior to onset of a 2-h free-choice between alcohol (15% v/v) and water. Alcohol was not available on weekends. The Pre-Drug Day was a Friday preceding Drug Days 1–5 (Monday–Friday of the following week) and Post-Drug Days 3 and 4 were on Monday and Tuesday of the week following termination of clonidine treatment.
EFFECTS OF CLONIDINE ON SACCHARIN INTAKEClonidine (40 µg/kg BW, IP) was injected on each of 3 consecutive days at 30 min prior to onset of a 2-h free-choice between water and saccharin solution (0.04 g/L). **p < 0.01 vs. saline control treatment, independent of treatment day.
No entities extracted from this document yet.
No uploaded files.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Endophenotypes for Alcohol Use Disorder: An Update on the Field. | 2015 | 26236574 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Activation of a locus coeruleus to ventral tegmental area noradrenergic pathway blunts binge-like ethanol intake and promotes aversive unconditioned responses in TH-ires-Cre mice. | Drinkuth CR et al. | — | 2026 | → |
| Alpha-2 Adrenergic Agonists Reduce Heavy Alcohol Drinking and Improve Cognitive Performance in Mice. | Quadir SG et al. | — | 2026 | → |
| Alcohol use disorder-associated pain: clinical and preclinical evidence. | Dong Y et al. | — | 2025 | → |
| GHSR blockade, but not reduction of peripherally circulating ghrelin via β<sub>1</sub>-adrenergic receptor antagonism, decreases binge-like alcohol drinking in mice. | Richardson RS et al. | — | 2025 | → |
| Agmatine alleviates ethanol withdrawal-associated cognitive impairment and neurochemical imbalance in rats. | Kale MB et al. | — | 2024 | → |
| Noradrenergic circuits and signaling in substance use disorders. | Downs AM et al. | — | 2022 | → |
| Drug addiction co-morbidity with alcohol: Neurobiological insights. | McGinn MA et al. | — | 2021 | → |
| Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development. | Koob GF | — | 2021 | → |
| Lateral hypothalamus-projecting noradrenergic locus coeruleus pathway modulates binge-like ethanol drinking in male and female TH-ires-cre mice. | Burnham NW et al. | — | 2021 | → |
| Behavioral, neurobiological, and neurochemical mechanisms of ethanol self-administration: A translational review. | Vena AA et al. | — | 2020 | → |
| Inhibitory influence of agmatine in ethanol withdrawal-induced depression in rats: Behavioral and neurochemical evidence. | Chimthanawala N et al. | — | 2020 | → |
| A Pathway-Based Genomic Approach to Identify Medications: Application to Alcohol Use Disorder. | Ferguson LB et al. | — | 2019 | → |
| Disabling the Gβγ-SNARE interaction disrupts GPCR-mediated presynaptic inhibition, leading to physiological and behavioral phenotypes. | Zurawski Z et al. | — | 2019 | → |
| Central Noradrenergic Interactions with Alcohol and Regulation of Alcohol-Related Behaviors. | Vazey EM et al. | — | 2018 | → |
| Disabling Gβγ SNARE interaction in transgenic mice disrupts GPCR-mediated presynaptic inhibition leading to physiological and behavioral phenotypes | Zurawski Z et al. | — | 2018 | — |
| Noradrenergic targets for the treatment of alcohol use disorder. | Haass-Koffler CL et al. | — | 2018 | → |
| Phosphoproteomic Analysis of the Amygdala Response to Adolescent Glucocorticoid Exposure Reveals G-Protein Coupled Receptor Kinase 2 as a Target for Reducing Motivation for Alcohol. | Bertholomey ML et al. | — | 2018 | → |
| Role of cortical alpha-2 adrenoceptors in alcohol withdrawal-induced depression and tricyclic antidepressants. | Getachew B et al. | — | 2017 | → |
| Serotonin-induced hypophagia is mediated via α<sub>2</sub> and β<sub>2</sub> adrenergic receptors in neonatal layer-type chickens. | Zendehdel M et al. | — | 2017 | → |
| A Genetic Animal Model of Alcoholism for Screening Medications to Treat Addiction. | Bell RL et al. | — | 2016 | → |
| Effects of idazoxan on alcohol pharmacokinetics and intoxication: a preliminary human laboratory study. | Haass-Koffler CL et al. | — | 2015 | → |
| Endophenotypes for Alcohol Use Disorder: An Update on the Field. | Salvatore JE et al. | — | 2015 | → |
| Prazosin + Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in P Rats with a Protracted History of Extensive Voluntary Alcohol Drinking, Dependence, and Multiple Withdrawals. | Rasmussen DD et al. | — | 2015 | → |